Doungdean Tummanatsakun, Tanakorn Proungvitaya, Temduang Limpaiboon, Sittiruk Roytrakul and Siriporn Proungvitaya
Khon Kaen University, Thailand
Liver Fluke and Cholangiocarcinoma Research Center- Khon Kaen University, Thailand
BIOTEC- NSTDA, Thailand
Scientific Tracks Abstracts: J Cancer Sci Ther
Cholangiocarcinoma (CCA) is a cancer from intra- and extra-hepatic biliary epithelial cells. The incidence of CCA in the northeastern part of Thailand is very high, especially Khon Kaen province. Metastasis of tumor provides important prognostic information and can help guide therapy. This study is to discover CCA prognosis marker to distinguish between non-metastatic and metastatic patients from our database in CCA cell lines secretome. Using bioinformatics include SignalP, SecretomeP, TMHMM, Plasma Proteome Database and EMBOSS for selected candidate proteins from three CCA secretome but not in control immortalized cholangiocyte by GeLC-MS/MS. Secretory protein was selected for further validation studies according to criteria including proteins predicted to have signal peptide or non-classical proteins that have no transmembrane helix, identified in serum and selected proteins with maximum of signal peptide cleavage sites. Apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) was selected for further validation analysis. APEX1 has been reported to play a role in metastatic function. Thus, to validate APEX1 protein was differentially expressed in CCA and western blot (WB) for APEX1 was performed for metastatic and non-metastatic group in serum CCA. This revealed that APEX1 intensity ratio was highly expressed in metastatic compared to non-metastatic group (4.73�±2.02 for metastatic vs. 1.14�±0.81 for non-metastatic group). In conclusion, serum APEX1 might be useful as a prognosis biomarker for treatment in CCA patients.
Doungdean Tummanatsakun is currently pursuing a Doctor of Philosophy Program in Medical Technology at the Faculty of Associated Medical Sciences, Khon Kaen University, Thailand. She is interested in cancer biomarkers.
Email: pui_ddlab41@hotmail.com
Cancer Science & Therapy received 3968 citations as per Google Scholar report